Home
All Journals
Expert Opinion on Investigational Drugs
List of Issues
Volume 19, Issue 1

Expert Opinion on Investigational Drugs

Search in:

Advanced search Citation search

Citation search

Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site
Instructions for authors
Editorial policies
Editing services site

Journal metrics
Aims & scope
Journal information
Editorial board
News & calls for papers
Advertising information

Latest articles
Current issue
All volumes & issues
Special issues
Open access articles
Most read articles
Most cited articles

New content alerts
RSS

Subscription options & pricing

Buy a subscription

Your download is now in progress and you may close this window

Did you know that with a free Taylor & Francis Online account you can gain access to the following benefits?

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Have an account?
Login now Don't have an account?
Register for free

Login or register to access this feature

Have an account?
Login now Don't have an account?
Register for free

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Expert Opinion on Investigational Drugs, Volume 19, Issue 1 (2010)

Browse this journal

Latest articles
Current issue
List of issues
Special issues
Open access articles
Most read articles
Most cited articles

Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Expert Opinion on Investigational Drugs, Volume 19, Issue 1 (2010)

See all volumes and issues

Vol 33, 2024 Vol 32, 2023 Vol 31, 2022 Vol 30, 2021 Vol 29, 2020 Vol 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Vol 22, 2013 Vol 21, 2012 Vol 20, 2011 Volume 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994

Select to download all citations or PDFs

Download citations Download PDFs Download issue

Browse by section (All)

Display order (Default)
Published online date
Page number
Section A-Z
Most read
Most cited

Discontinued Drugs Perspective

Article

Discontinued drugs in 2008: anti-infectives

Neil S Ryder PhD

Pages: 1-21

Published online: 10 Dec 2009

AbstractforDiscontinued drugs in 2008: anti-infectives | Full Text | References | PDF (417.9 KB)

255 Views
12 CrossRef citations
0Altmetric

Perspective

Article

Neuroimaging to assess safety and efficacy of AD therapies

Derek Hill

Pages: 23-26

Published online: 30 Nov 2009

AbstractforNeuroimaging to assess safety and efficacy of AD therapies | Full Text | References | PDF (203.1 KB)

82 Views
24 CrossRef citations
0Altmetric

Reviews

Article

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics

Puneet Chopra PhD, Gautam Sethi PhD, Sunanda G Dastidar PhD & Abhijit Ray PhD

Pages: 27-43

Published online: 10 Dec 2009

AbstractforPolo-like kinase inhibitors: an emerging opportunity for cancer therapeutics | Full Text | References | PDF (682.3 KB)

729 Views
95 CrossRef citations
0Altmetric

Article

Targeting voltage-gated sodium channels for pain therapy

Jeffrey J Clare PhD

Pages: 45-62

Published online: 10 Dec 2009

AbstractforTargeting voltage-gated sodium channels for pain therapy | Full Text | References | PDF (1.3 MB)

1023 Views
45 CrossRef citations
0Altmetric

Article

Investigational drugs for hepatitis C

Robert Flisiak MD PhD & Anna Parfieniuk MD

Pages: 63-75

Published online: 10 Dec 2009

AbstractforInvestigational drugs for hepatitis C | Full Text | References | PDF (269.7 KB)

158 Views
36 CrossRef citations
0Altmetric

Article

Targeting the transforming growth factor-β signaling pathway in human cancer

Nagathihalli S Nagaraj & Pran K Datta

Pages: 77-91

Published online: 10 Dec 2009

AbstractforTargeting the transforming growth factor-β signaling pathway in human cancer | Full Text | References | PDF (386 KB)

851 Views
205 CrossRef citations
0Altmetric

Article

Investigational drugs for allergic rhinitis

Giovanni Passalacqua MD, Enrico Compalati MD & Giorgio Walter Canonica MD

Pages: 93-103

Published online: 10 Dec 2009

AbstractforInvestigational drugs for allergic rhinitis | Full Text | References | PDF (337.4 KB)

169 Views
6 CrossRef citations
0Altmetric

Article

Novel TNF antagonists for the treatment of rheumatoid arthritis

Laisvyde Statkute MD & Eric M Ruderman MD

Pages: 105-115

Published online: 10 Dec 2009

AbstractforNovel TNF antagonists for the treatment of rheumatoid arthritis | Full Text | References | PDF (280.7 KB)

182 Views
11 CrossRef citations
0Altmetric

Article

Targeting cancer with phosphodiesterase inhibitors

Rajkumar Savai PhD, Soni Savai Pullamsetti PhD, Gamal-Andre Banat MD PhD MBA, Norbert Weissmann PhD, Hossein Ardeschir Ghofrani MD, Friedrich Grimminger & Ralph Theo Schermuly

Pages: 117-131

Published online: 10 Dec 2009

AbstractforTargeting cancer with phosphodiesterase inhibitors | Full Text | References | PDF (3.3 MB)

1209 Views
110 CrossRef citations
0Altmetric

Drug Evaluations

Article

Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

Carolyn F Deacon PhD & Jens J Holst MD

Pages: 133-140

Published online: 30 Nov 2009

AbstractforLinagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes | Full Text | References | PDF (261.8 KB)

1029 Views
107 CrossRef citations
0Altmetric

Article

Milatuzumab – a promising new immunotherapeutic agent

Zuzana Berkova, Rong-Hua Tao & Felipe Samaniego

Pages: 141-149

Published online: 07 Dec 2009

AbstractforMilatuzumab – a promising new immunotherapeutic agent | Full Text | References | PDF (340.3 KB)

579 Views
40 CrossRef citations
0Altmetric

Article

The efficacy and safety of telaprevir – a new protease inhibitor against hepatitis C virus

Ivan Gentile, Maria Aurora Carleo, Federico Borgia, Giuseppe Castaldo & Guglielmo Borgia

Pages: 151-159

Published online: 10 Dec 2009

AbstractforThe efficacy and safety of telaprevir – a new protease inhibitor against hepatitis C virus | Full Text | References | PDF (253.1 KB)

291 Views
46 CrossRef citations
0Altmetric

Article

Darapladib

Quang T Bui MD & Robert L Wilensky MD

Pages: 161-168

Published online: 10 Dec 2009

AbstractforDarapladib | Full Text | References | PDF (8 MB)

674 Views
11 CrossRef citations
0Altmetric

Explore articles

Latest
Open access
Most read
Most cited
Trending

Explore the most recently published articles

Inflammation and Huntington’s disease- a neglected therapeutic target?

Sophie E. Field et al.

Review Article | Published online: 17 May 2024

Drugs in preclinical and early clinical development for the treatment of Chagas´s disease: the current status

Fernanda Karoline Vieira da Silva Torchelsen et al.

Review Article | Published online: 14 May 2024

Emerging therapies for overactive bladder: preclinical, phase I and phase II studies

Samantha Gibson et al.

Review Article | Published online: 9 May 2024

Frontotemporal dementia: from genetics to therapeutic approaches

Francesca R. Buccellato et al.

Review Article | Published online: 9 May 2024

Open Access

View all latest articles

Download citations

Choose format

RIS (ProCit, Reference Manager)
BibTeX
RefWorks Direct Export

Download citations

Expert Opinion on Investigational Drugs (Vol.19, Iss.1, 2010)

Access Rights

Only articles that you have access rights to view will be downloaded. The green tick (full access) and orange padlock (open access) icons indicate that you have full access.

Do you want to proceed?